Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria

A. P. Kaplan, A. M. Giménez-Arnau, Sarbjit S Saini

Research output: Contribution to journalArticle

Abstract

The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.

Original languageEnglish (US)
JournalAllergy: European Journal of Allergy and Clinical Immunology
DOIs
StateAccepted/In press - 2016

Fingerprint

Urticaria
Immunoglobulin E
Basophils
Mast Cells
Autoantibodies
IgE Receptors
Histamine Antagonists
Autoantigens
Omalizumab
Down-Regulation
Immunoglobulin G
Antigens
Antibodies
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Chronic idiopathic urticaria
  • Chronic spontaneous urticaria
  • Omalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{4ab25ef298dd4cc3b75bec96ee78877b,
title = "Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria",
abstract = "The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.",
keywords = "Chronic idiopathic urticaria, Chronic spontaneous urticaria, Omalizumab",
author = "Kaplan, {A. P.} and Gim{\'e}nez-Arnau, {A. M.} and Saini, {Sarbjit S}",
year = "2016",
doi = "10.1111/all.13083",
language = "English (US)",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria

AU - Kaplan, A. P.

AU - Giménez-Arnau, A. M.

AU - Saini, Sarbjit S

PY - 2016

Y1 - 2016

N2 - The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.

AB - The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.

KW - Chronic idiopathic urticaria

KW - Chronic spontaneous urticaria

KW - Omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85007518600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007518600&partnerID=8YFLogxK

U2 - 10.1111/all.13083

DO - 10.1111/all.13083

M3 - Article

C2 - 27861988

AN - SCOPUS:85007518600

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

ER -